Rallybio (RLYB) EBITDA Yield: History & Chart

Rallybio Corporation(RLYB)

Biotechnology · New Haven, CT

$17.09+0.19 (+1.15%)

Delayed quote: Oct 6, 2026, 2:42 PM EDT

About Rallybio Corporation

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

New Haven, CT

7 employees

www.rallybio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stephen Uden

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Rallybio Corporation (RLYB)	$90.72M	N/A	N/A	N/A	N/A
Equillium, Inc. (EQ)vs ›	$90.73M	N/A	N/A	N/A	N/A
Biomea Fusion, Inc. (BMEA)vs ›	$91.07M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$90.20M	6.66%	6.57%	5.72%	4.64%
electroCore, Inc. (ECOR)vs ›	$89.26M	N/A	N/A	N/A	N/A
Conexeu Sciences Inc. (CNXU)vs ›	$92.32M	N/A	N/A	N/A	N/A
PMV Pharmaceuticals, Inc. (PMVP)vs ›	$89.33M	N/A	N/A	N/A	N/A
Park Dental Partners, Inc. Common Stock (PARK)vs ›	$92.47M	N/A	2.46%	2.46%	2.46%
CareCloud, Inc. (CCLD)vs ›	$89.02M	21.22%	23.06%	41.09%	38.38%
Neumora Therapeutics, Inc. Common Stock (NMRA)vs ›	$88.29M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Rallybio Corporation (RLYB)

$90.72M

N/A

Equillium, Inc. (EQ)vs ›

$90.73M

N/A

Biomea Fusion, Inc. (BMEA)vs ›

$91.07M

N/A

ImmuCell Corporation (ICCC)vs ›

$90.20M

6.66%

6.57%

5.72%

4.64%

electroCore, Inc. (ECOR)vs ›

$89.26M

N/A

Conexeu Sciences Inc. (CNXU)vs ›

$92.32M

N/A

PMV Pharmaceuticals, Inc. (PMVP)vs ›

$89.33M

N/A

Park Dental Partners, Inc. Common Stock (PARK)vs ›

$92.47M

N/A

2.46%

CareCloud, Inc. (CCLD)vs ›

$89.02M

21.22%

23.06%

41.09%

38.38%

Neumora Therapeutics, Inc. Common Stock (NMRA)vs ›

$88.29M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

RLYB EBITDA Yield Metrics

RLYB Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics